Entrada Therapeutics, Inc. (TRDA)
5.25
+0.56
(+11.94%)
USD |
NASDAQ |
Nov 10, 16:00
5.255
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Total Liabilities (Quarterly) : 68.56M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 68.56M |
| June 30, 2026 | 65.47M |
| March 31, 2026 | 64.66M |
| December 31, 2025 | 71.24M |
| September 30, 2025 | 72.18M |
| June 30, 2025 | 69.28M |
| March 31, 2025 | 69.22M |
| December 31, 2024 | 97.64M |
| September 30, 2024 | 132.14M |
| June 30, 2024 | 152.04M |
| March 31, 2024 | 241.48M |
| December 31, 2023 | 226.83M |
| Date | Value |
|---|---|
| September 30, 2023 | 238.37M |
| June 30, 2023 | 287.08M |
| March 31, 2023 | 245.96M |
| December 31, 2022 | 39.50M |
| September 30, 2022 | 41.24M |
| June 30, 2022 | 39.88M |
| March 31, 2022 | 39.31M |
| December 31, 2021 | 7.115M |
| September 30, 2021 | 7.497M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 3.359M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Prime Medicine, Inc. | 209.23M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.637B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 266.88M |
| Shareholders Equity (Quarterly) | 198.32M |
| Debt to Equity Ratio | 0.2386 |
| Current Ratio | 7.847 |
| Net Debt Paydown Yield | 0.60% |